NuCana
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 28
- Market Cap
- -
- Website
- http://www.nucana.com
- Introduction
NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 91
- Registration Number
- NCT05714553
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 182
- Registration Number
- NCT05678257
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 773
- Registration Number
- NCT04163900
- Locations
- 🇺🇸
University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸The Research Foundation for The State University of New York, Stony Brook, New York, United States
🇺🇸The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 135
- Registration Number
- NCT03829254
- Locations
- 🇬🇧
Freeman Hospital, Newcastle, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 107
- Registration Number
- NCT03428958
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Seattle Cancer Center, Seattle, Washington, United States
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 53
- Registration Number
- NCT03146663
- Locations
- 🇺🇸
Nashville Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States